文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

地度司他口服片治疗镰状细胞病的随机双盲安慰剂对照IIa期概念验证试验方案

Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation.
PubMed 文献 · Trials · 2026-05-09

本研究为IIa期、双盲、随机、安慰剂对照、平行组、概念验证、多中心临床试验,旨在评估地度司他(一种口服HIF-PHI)在印度成人镰状细胞病(SCD)患者中的疗效与安全性。共纳入24名受试者,按3:1随机分配至地度司他(50 mg、100 mg、150 mg三个剂量队列,每队列8人)或安慰剂组。主要疗效指标为第8周血红蛋白应答率相对于基线的变化。

要点

  • 地度司他为口服HIF-PHI,通过刺激促红细胞生成素产生、促进红细胞生成和改善铁代谢来发挥作用。
  • 试验设计为IIa期概念验证,纳入24例印度成人SCD患者,三个剂量队列各8人,随机按3:1分配至地度司他或安慰剂。
  • 治疗期为8周,第4周根据HemoCue校准仪测定的血红蛋白水平调整剂量,第8周评估血红蛋白应答率。

核心结论

  • 该IIa期概念验证试验旨在评估地度司他口服片在镰状细胞病成人患者中的疗效与安全性,结果可能有助于为SCD等罕见病建立成本效益好的治疗选择。

研究设计与样本

  • IIa期、双盲、随机、安慰剂对照、平行组、概念验证、多中心临床试验,在印度成人镰状细胞病患者中开展。
  • 共纳入24名受试者,按3:1随机分配至地度司他或安慰剂,地度司他设50 mg、100 mg、150 mg三个剂量队列,每队列8人。
  • 研究包括最长4周筛选期、8周治疗期和第10周随访,总计98天。

关键数值与推荐

  • 主要疗效指标为第8周血红蛋白应答率相对于基线的变化,与安慰剂比较。
  • 第4周根据地度司他组血红蛋白水平(使用校准的HemoCue仪器测定)进行剂量调整。
  • 地度司他口服片给药频率为每周3次,持续8周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle cell disease (SCD) is a genetic disorder characterized by chronic hemolysis and vaso-occlusive crises. Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has shown promise in treating SCD by stimulating erythropoietin production in a similar manner that happens in response to hypoxia, promoting erythropoiesis and improving iron metabolism, leading to increased hemoglobin and RBC indices. METHODS: This was a phase IIa, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept, multicenter clinical trial designed to evaluate the efficacy and safety of desidustat in Indian adults with sickle cell disease (SCD). A total of 24 participants were enrolled based on predefined eligibility criteria, with 8 subjects per dose cohort (50 mg, 100 mg, and 150 mg), randomized in a 3:1 ratio (desidustat:placebo). The study included a screening period of up to 4 weeks, an 8-week treatment phase, and a follow-up visit at week 10, totaling 98 days. Efficacy (hemoglobin response rate) was assessed at week 8 relative to baseline compared to placebo. Dose adjustment of desidustat at week 4 was guided by hemoglobin levels measured using a calibrated HemoCue instrument. DISCUSSION: Management of sickle cell disease (SCD) has limited treatment modalities available like hydroxyurea and blood transfusions. They offer benefits but their limitations underscore the ongoing need for safer, more effective, and accessible treatments. This proof-of-concept trial was conducted to investigate the efficacy and safety of desidustat oral tablet, 3 times per week for 8 weeks in SCD patients. Results from this trial could aid in establishing a cost-efficient therapeutic option for managing rare diseases like SCD. TRIAL REGISTRATION: The study was approved by Central Drugs Standard Control Organization (CDSCO: CT NOC number CT/SND/27/2023, protocol number DESI.23.001, version no. 01 registered on 12 June 2023) and was conducted for a new drug as per the GCP guidelines. The first subject was screened on 7 January 2025 and the last visit of the last subject was conducted on 31 July 2025, followed by clinical study report finalization on 29 September 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gangwar M, Kumar G, Roy S, et al. Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation. Trials. 2026. PMID: 42106815. doi:10.1186/s13063-026-09721-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。